Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Nanobiotix ( (NBTX) ) is now available.
Nanobiotix has announced the acquisition of shares by a key executive, Bartholomeus van Rhijn, which took place on December 9, 2024, at Euronext Paris. This transaction reflects the executive’s confidence in the company’s future prospects and could positively influence investor sentiment, given the significant volume of shares involved.
More about Nanobiotix
Nanobiotix is a company operating in the biopharmaceutical industry, focusing on developing nanomedicine products for cancer treatment. The company is known for its innovative approaches in enhancing radiotherapy efficacy using nanoparticles, targeting the oncology market.
YTD Price Performance: -53.30%
Average Trading Volume: 21,097
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $162.9M
For detailed information about NBTX stock, go to TipRanks’ Stock Analysis page.
